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INTRODUCTION:  Eccrine  spiradenomas  are  rare  adnexal  tumours  of  the  skin  that  originate  in  the  sweat
glands.  There  are  only  three  cases,  including  ours,  diagnosed  as malignant  transformation  in the breast.
PRESENTATION  OF CASE:  We  present  a case  of an  asymptomatic  48  year  old  woman  in  whom  the lesion
was detected  on  the  basis  of breast  cancer  prevention  programme.  The  metastatic  study  detection  and  the
sentinel  lymph  node  biopsy  were  negative  so  wide  excision  of the  mass  was  performed  with  no  further
treatment.  After  32 months  of  follow-up,  there  is  no  evidence  of recurrent  or metastatic  disease  in  our
patient.
DISCUSSION:  The  lesions  usually  show  a typical  history  of  a long-standing  unchanged  cutaneous  solitary
nodule  that  becomes  enlarged.  The  imaging  ﬁndings  of breast  eccrine  spiradenomas  have  not  been  clearly
demonstrated.  Diagnosis  is based  in histopathological  ﬁndings  of  malignant  focus.
A  large  list  of  uncommon  dermatological  skin  malignancies  and  breast  benign  lesions  can  mimic
malignant  eccrine  spiradenomas  (MES);  therefore,  determination  of  inmunophenotype  allows  narrow-
ing differential  diagnosis.  Distant  metastases  portend  an  ominous  prognosis.  The mainstay  of  treatment
is  surgical  removal  with  wide  excision  margins.  Radiation  and  hyperthermic  chemotherapy  can  also  be
administered  to prevent  focal  recurrence.  Due  to the  high  risk  of  developing  metastases,  close follow  up
of these  patients  for early  detection  of  recurrence  should  be carried  out.
CONCLUSION:  Eccrine  spiradenomas  are rare  adnexal  tumours  of the skin.  Intraparenquimatous  breast
location  is especially  infrequent.  Diagnosis  is based  on  histopathological  examination.  MES  metastasizes
(40%),  so  a close  follow  up  is  recommended.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Eccrine spiradenomas are rare adnexal tumours of the skin that
riginate in the sweat glands. Only a few cases have been reported,
eing described for the ﬁrst time by Kersting and Helming [1].
hough the majority of eccrine spiradenomas involve the head,
runk, and extremities [2], they can also appear all throughout
he skin, mostly as painless solitary nodules. Most interestingly,
ntraparenquimatous breast location is especially infrequent.
Our case report is a malignant eccrine spiradenoma
MES/spiradenocarcinoma) diagnosed in an asymptomatic woman
n the basis of breast cancer prevention programme. Because of
ts rare incidence and lack of imaging workups, there are only
wo previous reports of malignant breast spiradenoma. Our aim is
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therefore to discuss the main characteristics of it, and to review
the literature available on this issue.
2. Presentation of case
A 48-year-old woman, asymptomatic, with no medical history
of interest, presented in a mammography made as part of a breast
cancer screening programme a lesion in the left upper-breast. The
physical examination showed no palpable abnormalities, neither
signiﬁcant cutaneous change.
Plain radiographs revealed no calciﬁcations in the superﬁcial
soft tissue. Mammography (Fig. 1) demonstrated a well-deﬁned,
isodense nodule located in the upper-outer quadrant of the left
breast. No axillary lymphadenopathy was evidenced.
Sonographic examination of the patient was performed. Lon-
gitudinal and transverse scans with colour Doppler images were
obtained. The images (Fig. 2) showed a well-deﬁned lobulat-
ing mass measuring 18 × 13 × 15 mm  with homogeneous hypo
echogenicity. In the colour Doppler sonography no high vascular
s Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Mammography shows a well-deﬁned, isodense nodule.
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Fig. 3. Benign area is composed of two cell population.Fig. 2. US shows a well-deﬁned hipoechoic mass.
ow was seen. Fascial planes were preserved. Axillary lymph nodes
aintained preserved echostructure with cortical thickness less
han 3 mm.
The patient underwent a US-guided 14-gauge core needleiopsy for pathologic evaluation. A histologic examination of these
howed a characteristic biphasic population of outer small cells
ith darkly staining nuclei surrounding larger cells with paleFig. 4. Area of malignant transformation.
cytoplasm without epidermal connection. The histopathological
examination conﬁrmed the diagnosis of eccrine spiradenoma [1].
Subsequently, total excision of the mass was performed with
free resection margins. Intraoperative radiologic control of the
excised lesion showed integrity of the nodule with broad resection
margins.
Macroscopically the sample measured 4 × 2.5 cm in which on
serial sectioning a 2 × 1.5 cm white nodule was  noted.
Microscopic examination showed cells arranged in ragged
sheets, nests, cords, and solid masses along with occasional irreg-
ular glandular structures. Two  distinct cellular components were
identiﬁed. Benign areas, was  seen as sharply demarcated lob-
ules composed of 2 cell populations (peripheral basaloid cells and
central pale cells) arranged in nests with focal cystic changes.
Adjoining to this 2-cell population focus (gradually or abruptly)
proliferation cells with histopathological malignant characteristics
transited to solid masses of a homomorphous large cell popu-
lation with hiperchromatic and pleomorphic nuclei, eosinophilic
cytoplasm (Fig. 3). Mean number of mitotic ﬁgure was  10-15HPF
(high power ﬁelds). Invasion of the surrounding tissues character-
ize malignant transformation (Fig. 4). However, no lymphovascular
or perineural invasion was recognized. The overlaying epidermis
was unremarkable.
Inmunohistochemically, both cellular areas exhibited p63 and
were positive for smooth muscle actin (SMA). Focal reactivity for
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0Fig. 5. Positive inmunohistochemistry to Ki 67.
MA and CEA was found in the central, large, pale cells. Lumi-
al cells expressed MUC-1, CK 7, EMA, CEA, CK CAM5.2 and
CDFP-15. Around 40–50% of the cells composing the carcinoma-
ous area showed positivity to Ki-67 (Fig. 5), p53 and cyclin D1.
-100, CK 20, vimentin, CD3, cromogranin and CK34betaE12, estro-
en/progesterone receptors were not expressed.
These features were consistent with a low-grade MES  noted to
e arised from a pre-existing benign long-standing eccrine spirade-
oma.
The patient underwent sentinel node biopsy guided by isotopic
ymphogammagraphy. The sentinel lymph node retrieved from
xillary dissection was submitted for intraoperative histological
xamination obtaining a negative result for metastatic carcinoma.
Metastatic workup detection (bone scan, computed tomo-
raphic scans of the chest, abdomen, and pelvis) was also negative.
The patient has been seen in follow-up every 3–6 months and
as had yearly sonographic examinations. After 32 months of
ollow-up, there is no evidence of recurrent or metastatic disease.
. Discussion
Eccrine spiradenomas are usually benign, well-deﬁned sweat-
land neoplasms that affect both men  and women, showing no
ex predilection (male to female ratio 1:1) [2]. Age at presenta-
ion is variable, but most commonly arising at an age of 50 [2].
piradenoma lesions tend to arise on the head; neck; trunk; and,
ess commonly, the arms followed by the legs. The breast location is
xtremely rare [3]. However, the development of neoplasms with
ccrine sweat gland phenotype in the mammary ducts is not sur-
rising in as much as the breast is considered a modiﬁed sweat
land [6].
Since the original report, 102 cases of MES  [4] have been docu-
ented in the literature. Of these, only six are described affecting
he breast. There are only three cases, including ours, diagnosed as
alignant transformation in the breast (Table 1).
Although, four of the ﬁve cases of breast spiradenomas were
enign [7], 2 of these were reported to suffer malignant trans-
ormation, and one carcinosarcomatous conversion. Fortunately,
nly another case has demonstrated apocrine differentiation from
bdominal tumour.
Reviewing the reports, the lesions usually show a typical his-
ory of a long-standing (often decades); unchanged cutaneous
olitary nodule that suddenly becomes enlarged [5]. The average
ize of malignant spiradenomas at presentation is 3.9 cm (range
.5–15 cm)  in diameter, but usually 1–2 cm [8] as in our patient.PEN  ACCESS
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While pain is described as typical, this was  not noted in our patient.
The duration prior to diagnosis is usually long (20–30 years) [9].
It generally begets medical attention when a pre-existing undiag-
nosed lesion rapidly enlarges, changes colour, ulcerates, or becomes
painful and tender.
Our patient showed no physical complaints, and palpation noted
no pathological alterations.
The imaging ﬁndings of breast eccrine spiradenomas have
not been clearly demonstrated because of the rare incidence of
eccrine spiradenomas and the lack of imaging workup. The ﬁnd-
ings reported were: round or oval shape, well-demarcated masses
hypo, or hyper-dense in mammography [5]. The US ﬁndings of the
current case were characterized as well-circumscribed [5], oval-
shaped, hypoechoic masses, surrounded by echogenic lines that
represent the dermal layer.
Thomas et al. reported the ﬁrst description of the sonographic
ﬁndings of a MES  in 1993 as a hypoechoic, heterogeneous lesion
[5]. MRI, CT, and radiography can be used to assess the presence of
metastatic foci in the case of malignant spiradenoma.
Although, an eccrine spiradenoma may  resemble an epidermal
inclusion cyst on mammography and US, these may be identiﬁed on
the basis of MRI  ﬁndings. The MRI  [5] ﬁndings of epidermal inclu-
sion cysts and eccrine spiradenomas are different [8–10] and so
they might be used in making the differential diagnosis.
Diagnosis of MES  is based on histopathologic [11] examination
and requires ﬁnding a focus of benign spiradenoma within or adja-
cent to the malignant tumour.
Nowadays, histological ﬁndings distinguish high and low-
grade tumours. High-grade tumours show multiple foci of ﬂorid
squamous differentiation, including proliferation of solid masses
consisting of large cells with hyperchromatic nuclei, loss of PAS-
positive basement membrane, sarcomatous cell metaplasia and
surrounding cell reaction. The most aggressive forms are relatively
easy to diagnosis. The mesenchymal elements are non-speciﬁc
and are often described as rhabdomyosarcoma, osteosarcoma,
leiomyosarcoma, and chondrosarcoma.
On the other hand, in the absence of a benign focus, tumours
can be confused with other skin malignancies. The diagnosis of
these is much more difﬁcult and requires ﬁnding benign focus on
histopathology and an inmunohistochemical myoepithelial benign
proﬁle in consonance with the ﬁnding of two cell populations [12].
In our case, histologically proliferation of cells with hyperchro-
matic pleomorphic vesicular nuclei, variably prominent nucleoli,
increased mitoses, invasion of surrounding membrane and adipose
mammary tissue characterized malignant transformation.
Inmmunohistochemically, the cells express immunopheno-
types similar to mioepithelial cells with a variable expression of
p63 and SMA, and ductal differentiation cells expressing CEA, EMA,
CK7, MUC-1, CKCAM5.2 y GCDFP-15. S-100 [7] protein positivity
in basal epithelial cells has been demonstrated [2], but was not
evidenced in our case.
Biernat et al. suggest overexpression of p53 protein in MES has
been associated with malignant transformation [13]. We  also iden-
tiﬁed Ki-67 and D1-cyclin expression, as a result of a low-grade
differentiation tumour. While the inmmunohistochemical proﬁle
of benign or malignant eccrine spiradenoma is not diagnostic of an
eccrine neoplasm, it is helpful in elucidating the cellular differen-
tiation and narrowing the differential diagnosis.
The mainstay of treatment is surgical removal with wide exci-
sion margins [5]. Radiation and hyperthermic chemotherapy can
also be administered as medical treatment to prevent focal recur-
rence [5]. In our case, the wide excision performed permitted us to
dispense radiation treatment.
Malignant eccrine spiradenoma metastasizes (40%) [6] to
regional lymph nodes, bone, lungs, brain, and liver [14,15] (in
descending order of frequency). Therefore, regional lymph nodes
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Table 1
Summary of reported cases.
Age Type Primary location Symptoms Benign to
malignant
transformation
Lymphatic
invasion
Receptors
1993, Acta
chirurgica Belgica
42 MES  Breast Tumor, pain Yes 3 Lymph nodes EMA, cytokeratin
1996,  Archives of
Pathology
68 Carcinosarcoma Breast Tumor, colour
change, telorrhagia
Yes No lym-
phadenectomy
Spiradneoma:
cytokeratin
Rhabdomyosarcoma:
desmin, myoglobin
2004,  Annals of
Diagnostic
Pathology
57 MES  Breast Tumor, ulcer Yes No lym-
phadenectomy
Cytokeratin,
strogen and
progesterone in
20%, p53+++
2008,  Breast Cáncer 72 Metastatic MES  Abdominal wall Abdominal mass,
breast and armpit
umor
No N0/N7 Cytokeratin, CAM
5.2, 34bE12, CK7
umor,
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47 Benign eccrine
spiradenoma
Breast T
hould be dissected if tumor metastases are suspected clinically.
istant metastases portend an ominous prognosis, but if possi-
le, resection should be done. We  did not implement an axillary
issection, as sentinel node biopsy turned out negative.
Due to the high risk of developing metastases, close follow up
f these patients for early detection of recurrence should be carried
ut.
. Conclusion
Eccrine spiradenomas are rare adnexal tumors of the skin.
ntraparenquimatous breast location is especially infrequent. The
uration prior to diagnosis is usually long. Diagnosis of MES  is based
n histopathological examination. Malignant eccrine spiradenoma
etastasizes (40%), so a close follow up is recommended.
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